logo-loader

Avacta Group's Bach BioSciences deal 'an exciting step'

Published: 22:21 31 Jul 2018 AEST

Capital Network analyst Riccardo Lowi discusses Avacta Group Plc's (LON:AVCT) development partnership with Bach BioSciences as well as the news it's making shares available via subscription and a placing to bring in £11.4mln.

Lowi says the R&D collaboration with Bach is a very exiting step, potentially leading to a pre-clinical deal with big pharma in the next 12-18 month.

On Avacta's fundraise, he says the move should support operations well into calendar year 2020.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

5 hours, 9 minutes ago